vanoxerine
Small moleculeexperimental
Vanoxerine is an investigational drug which is being evaluated for the treatment of heart arrhythmias and cocaine dependence. Vanoxerine is a piperazine derivative which has multiple pharmacological activities including acting as an dopamine reuptake inhibitor, serotonin transporter inhibitor, and as a blocker of the cardiac hERG repolarizing potassium channel (IKr). — Wikipedia
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2002 (NCT00051896)
Timeline
Indications
Mechanism of action
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1- Mol. weight
- 450.57 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVanoxerine ↗
- ChEMBLCHEMBL281594 ↗
Also known as
- 1-(2 (bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine
- 1-(2 (bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride
- 1-(2-(bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine
- 1-(2-(bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine
- gbr 12909
- gbr 12909
- gbr 12909
- gbr-12909
- gbr-12909
- gbr-12909
- i 893
- i-893
- vanoxeamine
- vanoxerine
- vanoxerine
- vanoxerine
- vanoxerine
- vanoxerine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02454283 | Phase 3 | Sep 1, 2015 | Laguna Pharmaceuticals, Inc. |
| NCT01691313 | Phase 2 | Nov 1, 2012 | Laguna Pharmaceuticals, Inc. |
| NCT00218049 | Phase 1 | Dec 1, 2004 | National Institute on Drug Abuse (NIDA), The University of Texas, Dallas |
| NCT00100113 | Phase 1 | Jun 1, 2004 | National Institute on Drug Abuse (NIDA), University of Texas, Galveston |
| NCT00089687 | Phase 1 | Apr 1, 2004 | National Institute on Drug Abuse (NIDA), Uniformed Services University of Health Sciences |
| NCT00051896 | Phase 1 | Aug 1, 2002 | National Institute on Drug Abuse (NIDA), Uniformed Services University of Health Sciences |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Drug Abuse (NIDA) | Government | 4 | 4 | 1 | 2002 |
| Laguna Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2012 |
| Uniformed Services University of Health Sciences | Academic/Hospital | 2 | 0 | 1 | 2002 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Texas, Galveston | Academic/Hospital | 1 | 0 | 1 | 2004 |
5 organizations
Page 1 / 1